Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2025, titled 'Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma'.